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SDecial Article 
Fulminant Hepatic Failure: Summary of a Workshop 
JAY H. HOOFNAGLE,l ROBERT L. CARITHERS, JR,’ CRAIG SHAPIR0,3 AND NANCY ASCHER4 
Fulminant hepatic failure (FHF) is defined by the ap- 
pearance of severe liver injury with hepatic encephalop- 
athy in a previously healthy person. There are an esti- 
mated 2,000 cases of FHF in the United States yearly, 
representing 0.1% of all deaths and, perhaps, 6% of liver- 
related deaths. The causes of FHF are many, the chief 
ones in the United States being hepatitis A; B; non-A, 
non-B and drug induced liver disease. There are no spe- 
cific therapies for FHF, however, liver transplantation 
is recommended for situations in which spontaneous re- 
covery appears unlikely. Factors that are valuable in 
assessing the likelihood of spontaneous recovery are 
static features such as patient age and etiology of FHF 
and dynamic features including encephalopathy grade, 
prothrombin time, and serum bilirubin. Presently, ap- 
proximately 7% of all liver transplants are done for FHF 
and the 1-year patient survival rates average 63%, some- 
what less than survival rates for nonfulminant liver dis- 
ease, averaging 78%. The management of patients with 
F” is challenging, particularly important being moni- 
toring and early treatment of infections, hemodynamic 
abnormalities, and brain edema. Innovative approaches 
to management and therapy include use of cytoprotec- 
tive or antiviral medications, hepatic support systems, 
extracorporeal liver support, hepatocyte transplanta- 
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tion, auxiliary liver transplantation, and xenotransplan- 
tation. None of these are of proven benefit, but many are 
promising as a means to support the patient with FHF 
until spontaneous recovery occurs or a suitable liver 
graft is available for transplantation. (HEPATOLOGY 
1995;21:240-252.) 
Fulminant hepatic failure (FHF) is one of the more 
dramatic and challenging syndromes in clinical medi- 
cine. At present, there are no universally accepted cri- 
teria for the diagnosis of FHF. For practical purposes, 
FHF is defined by the appearance of severe acute liver 
disease with hepatic encephalopathy in a previously 
healthy person.’ Hepatic failure is often referred to as 
subfulminant if onset of encephalopathy occurs more 
than 8 weeks after onset of jaundice. FHF represents 
a clinical syndrome rather than a specific disease and 
can be caused by a variety of viruses, drugs, toxins, 
and metabolic disorders. 
The mortality rate of FHF is high, and there is no 
effective therapy for any of its major causes. Nonethe- 
less, medical therapy is critical in dealing with the 
many complications of FHF, including bacterial and 
fungal infections, hemodynamic instability, brain 
edema, renal and pulmonary failure, acid-base and 
electrolyte disturbances, and coagulopathy. Orthotopic 
liver transplantation (OLTx) has been used increas- 
ingly as an alternative to  conservative medical man- 
agement in patients with FHF in whom spontaneous 
survival is deemed to be unlikely. Critical in the deci- 
sion to use OLTx is the assessment of the likelihood of 
spontaneous recovery. OLTx commits the patient to a 
life-long need for immunosuppression to prevent graft 
rejection. The timing of OLTx in patients with FHF 
also is critical; a donor liver is often needed rapidly, and 
any delay can result in appearance of severe infectious 
complications or permanent neurological damage. Fi- 
nally, long-term survival after OLTx for FHF has been 
relatively poor in comparison with survival after OLTx 
for other conditions. These considerations make the 
role of OLTx in management of FHF particularly chal- 
lenging and controversial. New and better means of 
management are needed. 
On February 1 to 2, 1993, the National Digestive 
Diseases Advisory Board sponsored a workshop enti- 
tled “Current Issues in the Management of Fulminant 
Hepatic Failure” to address recommendations for the 
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current medical management of this condition, the role 
of OLTx, and the role of new and evolving innovative 
approaches in this challenging clinical condition. 
CAUSES OF FHF IN THE UNITED STATES 
The causes of FHF in the United States were dis- 
cussed by Dr Teresa Wright (Department of Medicine, 
Veterans Affairs Medical Center and University of Cal- 
ifornia, San Francisco, CA [UCSFI). FHF can be caused 
by viruses, drugs, toxins, and miscellaneous conditions, 
including Wilson's disease, Budd-Chiari syndrome, 
ischemia, and hyperthermia.' Identifying the cause of 
FHF in individual cases is important because of impli- 
cations for prognosis, therapy, and prevention. Diagno- 
sis requires application of intensive epidemiological, 
clinical and serological methods. The results of analysis 
of a cohort of 60 cases of FHF referred to UCSF between 
1989 and 1992 are shown in Table 1. 
In this series and in others, hepatitis A and B were 
the most frequently identified viruses causing FHF.' 
Although no cases were identified in this series, hepati- 
tis D and E account for a variable but usually small 
proportion of cases of FHF in Western countries. Most 
striking, however, was that hepatitis C did not account 
for a single case, despite the use of sensitive serological 
tests for hepatitis C virus (HCV) RNA as well as anti- 
body to HCV (anti-HCV). This low rate of fulminant 
hepatitis C has been found by others: in a recent sum- 
mary of four studies using tests for anti-HCV and HCV 
RNA, hepatitis C accounted for only 2% of cases of FHF 
(2 of 81 patients).2 Occasionally, chronic HCV infection 
appeared to be a cofactor with acute hepatitis B in 
causing FHF.3 
These findings, as well as results from other investi- 
gators, indicate that the single most common etiology 
of FHF is unknown. FHF can also be caused by other 
nonhepatotropic viruses, such as Epstein-Barr virus, 
cytomegalovirus, adenoviruses, and herpes simplex vi- 
rus, but these are exceedingly rare causes of FHF and 
usually present with distinctive clinical features. Pre- 
liminary findings suggesting that a paramyxovirus 
may account for some cases, especially those associated 
with giant-cell formation, remain un~onfirmed.~ Thus, 
most FHF in the United States is best described simply 
as cryptogenic. 
Some cases of cryptogenic FHF may actually be 
caused by hepatitis B. Mutations in critical hepatitis 
B virus (HBV) genes may cause a mutant virus that 
produces infection and disease but not hepatitis B sur- 
face antigens (HBsAg) or hepatitis B e antigens 
(HBeAg). For instance, the well-described HBeAg-neg- 
ative mutant of HBV, which has a mutation in the 
precore region that blocks synthesis of HBeAg, has 
been linked to FHF in several areas of the world. 
Omata et a15 found precore mutations in seven of seven 
Japanese patients with fulminant hepatitis B. Simi- 
larly, Liang et a16 found precore mutants in all five 
patients with FHF in an outbreak of hepatitis B in 
Israel. In Western countries, the precore mutant ap- 
pears to be less important as a cause of FHF.7 Further- 
more, it is not clear whether the precore mutant actu- 
ally predisposes patients to more severe hepatitis or 
whether these reports represent peculiar outbreaks. 
HBV mutants with defects in the HBsAg gene also 
have been described and may account for some cases 
of cryptogenic FHF.',' A number of investigators have 
found HBV DNA by Southern blot analysis in livers of 
HBsAg-negative patients with FHF. HBsAg was not 
detected in serum of these patients before OLTx, but 
the patients became positive for it after transplanta- 
tion. The role that these cryptic cases of hepatitis B 
play in the overall prevalence of FHF deserves further 
evaluation. 
Hepatitis E virus (HEV) infection is another poten- 
tial cause of FHF that might be missed by conventional 
serological testing. Hepatitis E can lead to FHF, partic- 
ularly in pregnant women. The methodology for diag- 
nosis of hepatitis E is still problematic. Among five 
studies from Western countries, hepatitis E was identi- 
fied in only two studies, and it accounted for only 6 of 
97 (6%) total cases.' 
Many drugs are capable of inducing FHF, and some 
cases of cryptogenic disease may be caused by exposure 
to a medication or toxin in the environment that is not 
considered significant or is not recognized or remem- 
bered by the patient. Careful toxicological screening 
may help detect some of these cases. Less common 
causes of FHF include Wilson's disease, shock or is- 
chemia, hyperthermia, hypothermia, Budd-Chiari syn- 
drome, malignancy, and the microsteatosis syndromes 
of fatty liver of pregnancy, Reye's syndrome, and drug- 
induced steatosis. The differential diagnosis of FHF 
should lead to  careful search for causes before the term 
cryptogenic is applied. 
However, despite intensive analysis and use of the 
most modern techniques, the cause of most cases of 
FHF remains unknown. This finding calls for further 
intensive research, using animal models as well as the 
most innovative molecular techniques, to  help define 
and eventually prevent or treat these unknown but 
important causes of FHF. 
EPIDEMIOLOGY 
The epidemiology of FHF in the United States was 
discussed by Dr Craig Shapiro (Medical Epidemiolo- 
gist, Hepatitis Branch, Centers for Disease Control and 
Prevention [CDC], Atlanta, GA). The most comprehen- 
sive system with data on the mortality from acute hepa- 
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TABLE 2. Estimated Deaths Caused by Acute Viral 
Heuatitis. United States 
TABLE 3. Number of Cases of OLTx for FHF 
by Year in the United States 
Case Estimated No. Estimated Year 1988 1989 1990 1991 
Total no. of OLTx 1,488 1,853 2,307 2,574 
Hepatitis A 0.2%-0.4%) 75,000 120-304 NO. O L T ~  for FHF (%I 110 126 167 149 
Hepatitis B 1.0%-1.2% 100,000 950-1,220 (7.4%) (6.8%) (7.2%) (5.8%) 
Total 212,500 1,640-2,474 
Type Fatality of Icteric Cases No. of Deaths 
Non-A, non-B 1.5%-2.5% 37,500 570-950 
titis and the incidence of hepatitis in the United States 
is the Viral Hepatitis Surveillance Program (VHSP), a 
nationwide system operated by the CDC that provides 
demographic, diagnostic, risk factor, and outcome in- 
formation on reported cases of acute viral hepatitis. 
Between 1983 and 1989,169,666 cases of acute hepati- 
tis were reported to the VHSP, of which 1,565 (.9%) 
were fatal." The fatality rate was lowest for hepatitis 
A (328 of 80,689, 0.4%), intermediate for hepatitis B 
(948 of 77,490,1.2%) and highest for non-A, non-B hep- 
atitis (289 of 11,487,2.5%). Age-specific rates indicated 
that mortality was higher in patients 50 years of age 
or older and in those younger than 5 years of age for 
all forms of hepatitis. Because this system relies on 
passive surveillance, reporting of cases is incomplete, 
and severe cases (including deaths) may be more likely 
to be reported than milder cases. Therefore, the calcu- 
lated fatality rates may be high. 
More accurate but geographically limited data on the 
incidence and mortality of acute viral hepatitis is avail- 
able from the Sentinel Counties Study, an intensive 
surveillance system for all cases of viral hepatitis in 
four counties in the United States.l12l2 In this system, 
patients with acute hepatitis are interviewed by 
trained personnel, and serum samples are obtained for 
special serological testing. Thus, more accurate demo- 
graphic characterization and diagnosis are possible. 
This important study has provided key information on 
the epidemiology, mode of transmission, pathogenesis, 
and natural history of acute and chronic viral hepatitis 
in the United States. Between 1982 and 1990, 11,226 
cases of acute hepatitis, of which 88 were fatal (0.8%), 
were entered into the Sentinel Counties Study. The 
mortality rate was 0.2% for hepatitis A (7 of 4,251 
cases), 1% for hepatitis B (42 of 4,410 cases), and 1.5% 
for non-A, non-B hepatitis (39 of 2,565 cases). 
The application of the case-fatality rates obtained 
from VHSP and the Sentinel Counties Study to the 
estimated annual number of cases of icteric hepatitis 
in the United States suggests that there are approxi- 
mately 2,000 deaths from acute viral hepatitis yearly 
(Table 2). 
Because FHF has causes other than acute hepatitis, 
surveillance systems have limitations in making infer- 
ences about the incidence of FHF. Two other systems 
can be used to assess mortality and morbidity of FHF: 
multiple cause of death data and the National Hospital 
Discharge Survey, both from the National Center for 
Health Statistics (NCHS). 13,14 
There are approximately 2 million deaths per year 
in the United States. Information on the major cause 
of death and on up to 20 contributing causes is included 
on all death certificates. There are no International 
Classification of Diseases-9th Revision, (ICD-9) codes 
specific for FHF. Using hepatic coma without mention 
of chronic liver disease, alcoholism, or neoplasm as an 
associated condition as a means of capturing cases, ap- 
proximately 7,489 deaths from FHF could be identified 
between 1980 and 1988, an incidence of 3.5 deaths 
caused by FHF per million people. Rates were higher 
for men than women and for blacks than whites. 
Statistics from the National Hospital Discharge Sur- 
vey include detailed information on discharge diagno- 
ses from 500 hospitals in the United States. Between 
1988 and 1990 there were an estimated 23,103 total 
hospital discharges coded as hepatic coma without 
mention of chronic liver disease, alcoholism, or neo- 
plasm. This estimate converts to a rate of 31.2 hospital- 
izations for FHF per million people. The average hospi- 
tal stay for this diagnosis was 17.5 days, yielding an 
estimated 135,000 hospital days per year. As with 
death certificate information, the rate of hospitaliza- 
tion for this diagnosis was higher in blacks than whites 
but was equal in men and women. 
Obviously, better information on the epidemiology 
and incidence of FHF is needed. The current reporting 
systems suggest that there are approximately 2,000 
deaths from FHF related to viral hepatitis yearly, 
which would represent approximately 0.1% of all 
deaths and perhaps 6% of liver-related deaths. 
CURRENT STATUS OF LIVER 
TRANSPLANTATION FOR FHF 
The current use of OLTx for FHF in the United 
States was reviewed by Dr Katherine Detre (Professor 
of Epidemiology, Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, PA). Information 
was obtained from the United Network for Organ Shar- 
ing (UNOS), which collects a limited amount of infor- 
mation on all transplantations performed in the United 
States.15 Supportive data is also available for the Na- 
tional Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) Liver Transplantation Database. l6 
According to information from UNOS, FHF accounts 
for approximately 7% of OLTx performed (Table 3). 
This indication for transplantation was more fre- 
quent for children (11% to 13%) than for adults (6% to 
7%). Overall, the median age of persons who received 
transplants for FHF (28 years) was lower than the me- 
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TABLE 4. Etiology of FHF in Patients Undergoing OLTx 
Etiology 
Children Adults 
(n = 146) (n = 424) 
Not specified 47.3% 25.9% 
Hepatitis A 10.3% 6.6% 
Hepatitis B 4.1% 23.4% 
3.8% 
Non-A, non-B hepatitis 26.7% 22.6% 
Drug-induced injury 9.6% 16.0% 
Other 2.1% 1.7% 
Hepatitis C - 
dian age for people who received transplants for other 
causes (44 years), this differential holding true even 
when adults were analyzed separately. FHF was a 
more frequent indication for OLTx for minority groups 
than it was for whites. 
The major cause of FHF leading to OLTx was un- 
known (‘‘not otherwise specified), followed by “non-A, 
non-B” hepatitis, hepatitis B, drugs, and hepatitis A 
(Table 4). Acetaminophen overdose or toxicity ac- 
counted for 2% of FHF cases in children and for 5% in 
adults. 
FHF patients undergoing OLTx were more likely to  
be on life support than were those undergoing trans- 
plantation for nonfulminant diseases (60% vs. 10% in 
adults), and the waiting time for transplantation was 
considerably shorter (mean, 5.3 days vs. 60.4 days in 
adults; 7.5 days vs. 106.1 days in children). Patients 
with FHF received liver transplants from donors with 
similar characteristics (age, cause of death, and so on), 
except for children, who were more likely to  receive 
a liver from an older donor if they had FHF. More 
importantly, however, patients with FHF were more 
likely to receive an incompatible blood group system 
(ABOkmatched donor (11% vs. 1.9% in adults; 17.7% 
vs. 5.7% in children). Finally, patients with FHF had 
lower rates of patient and graft survival than patients 
with nonfulminant disease (Table 5 ) .  
The relative risk for survival for 1 year for cases that 
received transplants for FHF was 1.89 (95% confidence 
interval [GI] = 1.66-2.15) for graft failure and 1.91 (95% 
GI = 1.65-2.21) for death indicating worse prognosis 
for OLTx for FHF than for other causes. However, 
when risk was adjusted for multiple factors that dif- 
fered between patients with FHF and those with other 
causes for OLTx, the relative risk decreased to approxi- 
mately 1.00 for both 1-year graft and patient survival. 
The most important factor was the recipient functional 
status, especially the need for life support. Age of the 
patient, donor age, cause of FHF, and pretransplanta- 
tion laboratory values did not appear to  correlate with 
poor outcome. Thus, survival after OLTx for FHF was 
not different than it was for other indications when the 
clinical condition of the patient was considered. 
PROGNOSTIC FEATURES IN FHF 
The decision to perform OLTx for a patient with FHF 
must take three questions into consideration: (1) Is 
spontaneous recovery probable? (2) If not, is trans- 
plantation feasible? (3) Or, have irretrievable complica- 
tions occurred? 
Spontaneous recovery is certainly the preferable out- 
come in FHF because most patients are left with no 
residual liver disease, and thus they avoid the risk and 
expense of the transplantation itself and the lifelong 
immunosuppressive therapy. On the other hand, recov- 
ery from FHF may not be possible, in which case urgent 
OLTx is the only option. Timing is critical to  successful 
transplantation; if OLTx is performed too early, it may 
not have been necessary; if it was performed too late, 
the patient with FHF may have already developed se- 
vere neurological damage or a life-threatening infec- 
tion. The critical decision of when to perform OLTx 
requires knowledge of accurate and sensitive prognos- 
tic factors for determining the likelihood of spontane- 
ous recovery. 
Predictive factors for survival in FHF were outlined 
by Robert L. Carithers, Jr, MD, (Department of Medi- 
cine, University of Washington, Seattle, WA). Prognos- 
tic factors for survival in FHF have been extensively 
analyzed in large series of patients from Boston,I7 Los 
Angeles,18 Paris,lg and London.20.21 From these studies, 
two types of clinical variables have been identified as 
helpful in assessing prognosis: static variables, which 
are present at  the time of admission and do not change 
(such as patient age, race, gender, and cause of dis- 
ease), and dynamic variables, which do change during 
the course of illness (such as degree of coma, serum 
bilirubin, and prothrombin time). 
Static variables that have been found to correlate 
with survival from FHF are patient age and etiology. 
Survival rate in patients between the ages of 10 and 
40 years is between 30% and 35%, whereas survival 
rate in patients older than 40 years of age or younger 
than 10 years of age is poor, less than 10%.17-21 Patients 
with hepatitis A and acetaminophen toxicity have the 
highest survival rate; those with hepatitis B and D 
have intermediate survival rates; and patients with 
drug-induced liver disease and with cryptogenic FHF 
have the poorest survival rates.’8-20 Patients with Wil- 
son’s disease or malignancy-induced FHF rarely sur- 
vive. 
Dynamic variables useful in predicting the outcome 
of FHF include degree of hepatic encephalopathy, pro- 
thrombin time, factor V level, serum bilirubin, serum 
creatinine, alpha-fetoprotein level, arterial pH, and ar- 
terial ketone body ratio.’’ The degree of encephalopa- 
thy is a strong predictor of outcome. Among patients 
who reach only stage I1 encephalopathy, the possibility 
of spontaneous recovery is between 65% and 70%, with 




All FHF cases 63% 
All non-FHF cases 78% 
53% 
70% 
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stage I11 between 40% and 50%, and with stage IV 20% 
or 10wer.l~ 
In recent years, sophisticated multivariate analysis 
and prognostic modelling have been applied to static 
and dynamic variables to assess the relative impor- 
tance and interaction in predicting outcome. Bernuau 
et all9 from the H8pital Beaujon, Clinchy, France, ana- 
lyzed features from 115 consecutive patients with FHF 
caused by hepatitis B. Variables found to correlate best 
with survival were the factor V level (P  < .001), patient 
age (P  = .001), absence of HBsAg (P  = .06), and level 
of alpha-fetoprotein ( P  = .07). Subsequently, Williams 
et a1 from the King's College Liver Unit (London) ana- 
lyzed data on 588 patients admitted with FHF to their 
care, 310 of whom had acetaminophen toxicity.20,21 For 
the total cohort, the static variables found to be most 
important in predicting prognosis were patient age (P 
< .Ol), disease etiology (P < .001), encephalopathy 
grade (P  < .05), and, for nonacetaminophen cases, du- 
ration ofjaundice (P < .001). Analysis of dynamic vari- 
ables showed that admission and peak serum bilirubin 
and prothrombin times were important. In patients 
with acetaminophen-induced FHF, arterial pH on ad- 
mission and serum creatinine were also important. 
Based on their multivariate analysis, the King's Col- 
lege group have proposed the following criteria for 
transplantation in patients with FHF.20,21 For acet- 
aminophen hepatotoxicity: Arterial pH <7.30 or the 
following three factors: prothrombin time > 100 sec- 
onds, creatinine >3.5 mg%, and grade I11 or IV enceph- 
alopathy. For other causes of FHF: Prothrombin time 
>lo0  seconds or any three of the following: prothrom- 
bin time >50 seconds, bilirubin >17.5 mg% (100 pmol), 
age younger than 10 years or older than 40 years, 
cryptogenic or drug-induced FHF, or  jaundice for more 
than 7 days before onset of encephalopathy. 
Using both static and dynamic variables, important 
information of prognosis can be gained to estimate the 
probability of spontaneous recovery. These carefully 
defined criteria for judging prognosis are extremely val- 
uable but need to be continuously re-evaluated and re- 
vised based on other advances in the management of 
FHF. 
COMPLICATIONS OF FHF 
The medical complications of FHF were discussed by 
Andres Blei, MD (Department of Medicine, Lakeside 
VA Medical Center and Northwestern Medical Center, 
Chicago, IL), and new approaches to their management 
were discussed by Gregory Gores, MD (Division of Gas- 
troenterology, Mayo Clinic, Rochester, MN). Common 
complications of FHF include infections, hemodynamic 
changes, mental status changes, and brain edema. 
Infections. Infections are a common complication 
and significant cause of death in patients with FHF. 
In a prospective study of 50 patients with FHF who 
had daily bacterial cultures, investigators at the FHF 
unit at King's College found evidence of infection in 
90% of  patient^.'^ A third of patients had fungal infec- 
tions in addition to bacterial infections. Most patients 
had few systemic manifestations of infections such as 
fever or elevated white blood cell counts. Thus, without 
careful monitoring and routine cultures, many infec- 
tions can be missed before death. 
Spontaneous bacterial peritonitis also is common 
among patients with FHF. Chu et alZ4 found that 32% 
of 82 patients with severe acute hepatitis and subacute 
hepatic necrosis developed bacterial peritonitis. Pa- 
tients with peritonitis or other infections were more 
likely to develop renal failure and gastrointestinal 
bleeding and had a significantly higher mortality than 
did noninfected patients. 
The frequency of severe infections during the course 
of FHF has led to trials of preventive therapy. Prophy- 
lactic therapies have focused on control of bowel flora, 
the suspected source of most bacteremias in FHF. In 
a controlled trial from the King's College FHF group, 
prophylactic antibiotics led to  a significant decrease in 
bacterial infections. Although survival was greater in 
patients given prophylactic antibiotics, this did not 
reach statistical ~ignificance.'~ However, the rate of 
successful transplantation was greater in patients 
given antibiotics, and the investigators concluded that 
prophylaxis was appropriate for all patients with FHF 
and stage I11 encephalopathy. In a separate study from 
Barcelona, Spain, investigators found that broad-spec- 
trum antibiotics led to  a decrease in mortality rate and 
shortened hospital time in patients with FHF.26 Thus, 
two recent controlled trials indicate that prophylactic 
antibiotics are appropriate in the management of FHF. 
Hemodynamic Changes. Patients with FHF can 
experience marked changes in systemic and portal 
hemodynamics, including acute portal hypertension, 
systemic hyperdynamic circulation, and profound pe- 
ripheral vasodilation. For instance, in one study, portal 
hypertension was present in 24 of 25 patients with FHF 
who underwent hepatic venous pressure measure- 
m e n t ~ . ~ ~  Raised portal pressures correlated with the 
degree of architectural disruption of the liver and were 
most evident in patients with ascites and renal failure. 
Patients with FHF typically had a hyperdynamic circu- 
lation with a low systemic vascular resistance and 
markedly increased cardiac output similar to what is 
found in chronic liver disease. The cause of these circu- 
latory changes are unclear; from studies of chronic liver 
disease, a variety of mediators have been proposed, 
including bile salts, prostaglandins, glucagon, endo- 
toxin, serotonin, nitric oxide, and nonhumoral neural 
substances. The circulatory changes, which can be pro- 
found, are associated with renal vasoconstriction, a de- 
crease in cerebral perfusion pressure (CPP), and hepa- 
topulmonary syndrome. The renal vasoconstriction 
leads to  a picture of renal failure similar to  the hepato- 
renal syndrome observed in chronic liver disease. In 
addition, prolonged inappropriate arteriolar vasodila- 
tation can interfere with the normal autoregulation of 
capillary oxygen consumption and predispose the pa- 
tient to lactic acidosis. 
In one clinical trial," prophylactic acetylcysteine or 
placebo was administered to 50 patients with acet- 
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aminophen-induced FHF in an attempt to decrease tis- 
sue injury by augmenting intracellular sources of cys- 
teine and glutathione. Therapy was associated with an 
increase in oxygen delivery and a decrease in lactic 
acidosis although cardiac output was increased and pe- 
ripheral vascular resistance was further de~reased.'~ 
Brain Edema. In addition to encephalopathy, FHF 
is commonly associated with brain edema, which can 
evolve to an increase in intracerebral pressures (ICP), 
a common immediate cause of death in FHF. Increased 
ICP is uncommon in patients with stage I and I1 en- 
cephalopathy but eventuates in the majority of patients 
in stage IV coma. It is clear that there is an increase 
in brain water before brain edema becomes clinically 
apparent as increased ICP. 
The cause of brain edema in FHF is not well defined; 
but it is probably multifactorial. Theoretically, it could 
be caused either by disruption of the blood-brain bar- 
rier with direct leakage of plasma into the cerebrospi- 
nal fluid (CSF) (vasogenic mechanism) or by cellular 
alterations that allow increased uptake of water into 
brain cells (cytotoxic mechanism). The majority of ex- 
perimental evidence favors the latter mechanism, a 
concept that is supported by clinical observations that 
mannitol is effective and corticosteroids are ineffective 
in reducing ICP in FHF. Three hypotheses have been 
proposed to explain the cellular defect that leads to 
brain edema in FHF: (1) inhibition of Na'-K' adeno- 
sine triphosphatase (ATPase) activity; (2) astrocyte 
swelling; and (3) osmotic effects of accumulation of an 
intracellular molecule, possibly gl~tamine."-~~ 
Further studies on the cause and prevention of com- 
plications of acute liver injury are needed. Three major 
areas deserve particular emphasis: (1) prevention of 
infections; (2) analysis of the prognostic implications 
of hemodynamic changes, renal failure, and metabolic 
acidosis; and (3) understanding the pathogenesis of 
brain edema. Optimal management of these complica- 
tions of FHF may well lead to improvements in sur- 
vival. 
INTRACEREBRAL PRESSURE 
MONITORING IN FHF 
The major cause of death in patients with FHF 
awaiting liver transplantation is brain edema. Further- 
more, brain edema is found on autopsy in 80% of pa- 
tients dying of FHF. Dr John Lake (Department of 
Medicine, University of California, San Francisco, CA) 
summarized recent findings using ICP monitoring, 
which has been increasingly used in patients with FHF 
to allow for proper management of brain edema and to 
aid in the decision to perform OLTx. 
ICP monitoring had its foundation in the manage- 
ment of Reye's syndrome in the 1960s and 1 9 7 0 ~ ~ ~  
These studies indicated that if cerebral perfusion pres- 
sure (CPP = mean arterial pressure - ICP) remained 
<40 mm Hg, death or severe neurological complica- 
tions were all but certain. Concerns over complications 
of inserting ICP monitors led to attempts to develop 
clinical findings indicative of a low CPP. Sluggish pu- 
pillary reflexes, hyperventilation, and increased sys- 
temic blood pressure occur early with increasing ICP. 
Myoclonus, increased muscle tone, decorticate postur- 
ing, and seizures occur late. In studies of ICP at King's 
College, clinical manifestations commonly occurred 
with ICP of greater than 30 mm Hg, but there was a 
poor correlation between the height of the ICP and 
specific clinical signs.33334 Computed tomography (CT) 
scan of the brain has likewise been found to be unrelia- 
ble in detecting early brain edema. Furthermore, trans- 
port of the patient to the radiology department for CT 
scan can precipitate increases in ICP and neurological 
damage. 
Slightly more than half of transplantation programs 
in the United States routinely use ICP monitoring in 
management of cases of FHF. Three types of monitors 
have been used: epidural, subdural, and parenchymal. 
The epidural monitor is outside the dura and, there- 
fore, is less invasive and has fewer complications. How- 
ever, it is also somewhat less reliable than the subdural 
or parenchymal monitors. ICP monitoring has compli- 
cations. A recent review of ICP rnon i t~ r ing~~  indicated 
that the complication rates were 4% (6 of 160) for epi- 
dural, 20% (16 of 79) for subdural, and 22% (5 of 23) 
for parenchymal monitors. Deaths from infection or 
bleeding were reported with all three types of monitor- 
ing but were less common with the epidural (-1%) 
than with others (4% to  5%). 
In many transplantation centers, epidural monitor- 
ing has become a standard practice for patients with 
FHF.36 The monitor is placed at the onset of stage IV 
coma or if there is rapid progression into stage I11 coma. 
A brain CT scan is performed before placement, and 
any coagulopathy is corrected with fresh frozen plasma 
(to keep prothrombin time <5 seconds prolonged). The 
epidural ICP monitor is checked daily by neurosurgical 
consultants. A repeat CT scan is performed at removal 
of the ICP monitor. 
ICP monitoring is valuable in guiding treatment, the 
goals of which are to maintain an ICP of <20 mm Hg 
and a CPP of >50 mm Hg. A standardized approach 
to therapy has been adopted by the collaborating cen- 
ters of the NIDDK Liver Transplantation 
If the ICP rises above 20 mm Hg, (1) patients are hyper- 
ventilated to keep the P C O ~  less than 25 mm Hg. If 
there is no response or a relapse, (2) mannitol is admin- 
istered (0.5 to 1 gkg) as a bolus intravenously and then 
as needed to keep serum osmolarity between 310 and 
320 mOsm. If there is no response or a relapse with 
mannitol, (3) pentobarbital coma is induced using a 
bolus of 3 to  5 mgkg intravenously. Although the re- 
sponse rate to  therapy was high, relapses were common 
(Table 6). 
ICP monitoring not only allows for rapid and appro- 
priate therapy of brain edema but also for avoidance 
of manipulations that worsen ICP, such as excessive 
physical stimulation, suctioning of the airway, or 
changes in body position. ICP monitoring also has been 
helpful during the transplantation procedure to  deter- 
mine which anesthetic agents affect ICP the least. 
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TABLE 6. Outcome of ICP Monitoring in Patients With FHF 
Treatment No. of Episodes % of Response Initial Pressure (Mean) Change Pressure (Mean) % of Relapse 
Hyperventilation 18 82% 18 mm 3.5 mm 7 1% 
Mannitol 11 72% 26 mm 4.6 mm 75% 
Barbiturate coma 15 73% 26 mm 4.6 mm 80% 
From these studies, narcotics and barbiturates have 
been preferred to  inhalation gases for anesthesia induc- 
tion, and P-blockers have been preferred to nitroprus- 
side for blood pressure control. 
The value of ICP monitoring in selecting patients for 
OLTx has recently been documented in studies at the 
University of Nebraska, Omaha, NE.38 When ICP mon- 
itoring was introduced, the results were not used to 
decide which patients should or should not undergo 
OLTx. During this early period, seven patients with a 
CPP < 40 mm for more than 2 hours received trans- 
plants; all seven suffered brain death. Conversely, all 
patients whose CPPs remained >50 mm recovered 
without neurological sequelae. Subsequently, no pa- 
tients with low CPP for more than 2 hours received 
transplants, and none of those who underwent trans- 
plantation developed severe neurological sequelae. 
Thus, ICP monitoring can be accomplished safely, is 
more reliable than CT scans, electroencephalograms, 
or neurological examination, and has excellent sensi- 
tivity and specificity in predicting brain injury. Moni- 
toring can guide therapy of brain edema, avoiding 
harmful manipulations as well as titrating therapeutic 
decisions. ICP monitoring provides reliable criteria for 
avoidance of OLTx in patients with irreversible brain 
damage and provides evidence of impending brain 
death. 
OLTx FOR F H F  UCSF EXPERIENCE 
The experience in managing patients with FHF us- 
ing OLTx at the UCSF was reported by Dr Nancy 
Ascher (Department of Surgery, UCSF 1. Results using 
an organized medical-surgical-transplantation ap- 
proach have been excellent.37 The approach focuses on 
prompt diagnosis, prospective monitoring of ICP, ag- 
gressive treatment of complications, and early listing 
for liver transplantation. If patients have prolonged 
periods of compromised intracranial perfusion, they 
are removed from the transplantation list. 
Between 1988 and 1992,60 patients with FHF were 
evaluated for possible OLTx for FHF. Among 24 who 
presented with stage I1 to  I11 encephalopathy, 11 re- 
ceived transplants (2 others died, and 11 recovered 
spontaneously). Among 36 patients presenting in stage 
IV coma, 17 received transplants (16 others died, and 
3 recovered without OLTx). Donor livers were obtained 
quickly, 15 within 1 day of listing and 13 more within 
1 to 3 days. The l-year patient survival rate was 92%, 
and the graft survival rate was 83%. The 3 deaths were 
caused by (1) aspiration pneumonia and cytomegalovi- 
rus infection at 5 months, (2) aspergillus brain abscess 
at  If months, and ( 3 )  progressive cerebral edema after 
primary nonfunction at 3 days after OLTx. Graft fail- 
ures were frequent, perhaps because of the use of ABO- 
incompatible livers. The 7 graft failures leading to re- 
transplantation were caused by vascular rejection (2 
patients), acute rejection (2 patients), chronic rejection 
(1 patient), and acute hepatitis B (2 patients). Neuro- 
logical sequelae were mild and limited to only 2 pa- 
tients. Other chronic complications included (1) a pa- 
tient with fulminant cryptogenic hepatitis who 
developed chronic hepatitis B with compensated cirrho- 
sis 2; years after transplantation; (2) a patient with 
fulminant hepatitis A who developed chronic hepatitis 
C but who has normal liver function tests 2 years after 
transplantation; and (3) 2 patients with fulminant hep- 
atitis B who have developed cirrhosis with normal en- 
zymes at 3 years after transplantation. 
Survival results in patients with FHF who under- 
went transplantation at UCSF have been comparable 
with those of patients with nonfulminant diseases. 
These data show that excellent results can be achieved 
with OLTx for FHF when strict criteria are used for 
selection and when patients' conditions are managed 
with an organized and aggressive approach. 
AUXILIARY LIVER TRANSPLANTATION 
OLTx for FHF requires that the damaged liver be 
removed and that the patient be committed to a life- 
time of immunosuppression. The possibility of recovery 
from FHF makes attractive the option of auxiliary liver 
transplantation, in which the native liver is left in 
place. Dr Bruce Jarrell (Chairman of Surgery, Univer- 
sity of Arizona Health Science Center, Tucson, AZ) pro- 
vided an overview of auxiliary liver transplantation for 
FHF. 
The advantages of auxiliary transplantation in FHF 
are the temporary requirement for immunosuppression 
drugs until the host liver recovers and the relative ease 
of surgery. Two types of auxiliary liver support are 
possible: heterotopic and orthotopic. 
In auxiliary heterotopic transplantation, the liver 
graft is placed in the right upper quadrant beside the 
native liver. In orthotopic auxiliary transplantation, a 
portion of the native liver is removed and replaced with 
a reduced-size graft. Auxiliary heterotopic transplanta- 
tion is technically easier than orthotopic transplanta- 
tion but suffers from competition between the graft and 
native liver for portal blood supply, the tenuous nature 
of the blood supply to the graft, problems of venous 
congestion, and potential lack of space. In recent years, 
there have been seven reports of heterotopic trans- 
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plants for FHF. Three patients died shortly after trans- 
plantation; four are living, and three have had recovery 
of the native liver and have stopped immunosuppres- 
sion. Recovery of the native livers occurred at 5 months, 
6 months, and 22 months, respectively.39340 
The major difficulties with auxiliary orthotopic 
transplantation relate to the technical difficulties in- 
volved in resection of the left lateral segment of the 
native liver and placement of the graft (frequently a 
reduced-size graft) at that site.41 This operation is par- 
ticularly difficult in unstable patients with FHF and 
severe coagulopathy. However, the auxiliary orthotopic 
transplant has a more secure portal blood supply than 
the heterotopic transplant. Among seven patients from 
Hanover, Germany, and Nebraska that have been re- 
ported, three s~rvived.~ '  Two deaths were caused by 
development of aplastic anemia in patients with fulmi- 
nant cryptogenic hepatitis. 
In summary, auxiliary liver transplantation has 
been used successfully in 7 of 12 patients (60%) with 
FHF. Several technical problems with auxiliary trans- 
plantation need further evaluation. The advantages of 
not taking immunosuppressive drugs chronically may 
prove important once the overall survival of this tech- 
nique has sufficiently improved. 
ARTIFICIAL HEPATIC SUPPORT SYSTEMS 
In recent years, there has been an increased interest 
in the use of hepatic support systems in patients with 
FHF to provide a bridge until the native liver recovers 
function spontaneously or until an appropriate donor 
liver is available. Breakthroughs in basic and applied 
research have provided innovative approaches to  the 
possibility of artificial hepatic s ~ p p o r t . ~ ~ , ~ ~  Use of a cell- 
based therapy for extracorporeal hepatic support was 
discussed by Dr Norman Sussman (Assistant Profes- 
sor, Department of Medicine and Pathology, Baylor 
College of Medicine, Houston, TX). 
Initial attempts at developing an artificial hepatic 
support were focused on various forms of dialysis or 
hemoperfusion using cartridges and membranes that 
would remove low -molecular weight Charcoal 
hemoperfusion enjoyed considerable attention in the 
late 1970s and early 1980s, but subsequent careful 
evaluations failed to show evidence of benefit of the 
 procedure^,^^^^^ suggesting that something more than 
removal of toxins was required to prolong life in he- 
patic-failure patients. These considerations led to in- 
vestigation of extracorporeal-assist devices that might 
provide both detoxifying and synthetic hepatic func- 
tions. The major focus of interest has been the use of 
cell-based extracorporeal devices. 
Several types and sources of hepatocytes have been 
investigated for use in extracorporeal-assist devices. 
The ideal hepatocyte would be (1) human in origin, (2) 
of normal (nonmalignant) phenotype, (3) readily avail- 
able, (4) rapidly and easily grown in cell culture to  high 
density, ( 5 )  stable and remaining in a well-differenti- 
ated state for days or weeks, and (6) capable of the full 
range of synthetic and detoxifying features of mature 
hepatocytes. Of course, the ideal hepatocyte for these 
devices has not been identified. Normal human hepato- 
cytes are not readily available, grow slowly in primary 
cell culture, rarely survive for more than a few weeks, 
and usually rapidly lose their differentiated state and 
metabolic functions. Alternatives to primary human 
hepatocytes have been primary hepatocytes from other 
mammalian species (pig, rat, and dog) and immortal- 
ized human liver cell lines. 
Sussman et a145 have investigated a human hepa- 
toblastoma cell line (C3A cells) that shows many char- 
acteristics of differentiated mature hepatocytes, in- 
cluding contact inhibition, detoxification of ammonia 
to  urea and glutamine, metabolism of amino acids, glu- 
coneogenesis, and integrity of the P450 system. They 
have reported the development of a hepatocyte-assist 
device using C3A cells grown in the extracapillary 
space of a hollow-fiber dialyzer. The device has the met- 
abolic capacity of approximately 200 g of normal liver. 
In preliminary studies in a dog model of FHF with 
100% mortality, the assist device led to  recovery of 
consciousness, decreases in alanine aminotransfer- 
ase(ALT) levels, and survival in four of five animals. 
Preliminary attempts to use the C3A-based hepato- 
cyte-assist device in humans with severe liver failure 
also were reported.46 The system used is similar to  he- 
modialysis: venous blood is pumped through hollow fi- 
bers and returned to the patient at a flow rate of ap- 
proximately 150 mumin. A second flow path is 
maintained by the continuous ultrafiltration of plasma 
into the extracapillary space at a rate of 20 mllmin. 
The metabolic effects of the cartridge appear to be inde- 
pendent of ultrafiltration; delivering the ultrafiltrate 
back to the blood stream allows efficient delivery of 
high-molecular weight products such as clotting fac- 
tors. 
To date, six patients have been treated with the he- 
patic-assist device. Improvements in serum ALT levels, 
prothrombin time, galactose-elimination capacity, and 
clinical status were noted in five patients during use 
for 1 to 6 days on a continuous basis. Only one patient 
survived, a 12-year-old girl with syncytial giant-cell 
hepatitis who recovered without OLTx after 58 hours 
on the assist device and who is alive and well 1 year 
later. A second patient appeared to recover from FHF 
but succumbed to sepsis several days later. The re- 
maining patients died without OLTx. 
Other hepatic-assist devices are being evaluated. De- 
metriou et a147 have recently reported successful treat- 
ment of FHF in dogs with a hepatic-assist device using 
primary pig hepatocytes. This experience is now being 
applied to humans with FHF.4s Thus, new refinements 
in cell-based hepatic-assist devices have provided new 
hope for this approach to medical therapy of FHF. 
HEPATOCYTE TRANSPLANTATION 
Achilles A. Demetriou, MD, PhD (Director of Liver 
Support Unit, Cedars Sinai Medical Center, Los 
Angeles, CA), discussed the use of hepatocyte trans- 
plantation for management of FHF. This innovative 
Tv January 1995 
alternative approach uses transplantation of hepato- 
cytes rather than of the whole organ. This approach 
would have the advantages of avoiding both major sur- 
gery and the use of a whole liver; it is technically simple 
and allows the use of one or more living-related donors 
and multiple courses of treatment. This technique also 
might providve temporary hepatic support without com- 
mitting the patient to lifelong immunosuppression. He- 
patocyte transplantation has not been used in humans 
with liver disease but has been applied with partial 
success in several animal models of liver diseases. 
The feasibility of hepatocyte transplantation has 
been documented in studies of genetically deficient ani- 
mals. Transplantation of normal rat hepatocytes by in- 
traportal infusion into analbuminic rats was followed 
by increasing levels of serum albumin 14 to 28 days 
later, which persisted for several months.49 Similarly, 
in jaundiced Gunn rats with genetic deficiency of glu- 
curonyl transferase (an animal model of Criggler- 
Najjar syndrome), transplantation of hepatocytes from 
normal rats resulted in decreases in serum bilirubin 
levels and appearance of conjugated bilirubin in the 
bile.50 These studies have documented the long-term 
viability of transplanted hepatocytes and identified 
problems in optimizing the technique. For example, the 
number and percentage of cells surviving can be in- 
creased by using hepatocytes attached to beads coated 
with a collagen matrix.51 However, these cells remain 
immunogenic, and if allogeneic hepatocytes are used, 
a lasting problem will be the need for immunosuppres- 
sion. Rejection can be partially circumvented by micro- 
encapsulation of hepa to~ytes~~;  unfortunately, the mi- 
crocapsules usually induce an intense inflammatory 
reaction that results in poor hepatocyte function. The 
site of infusion of hepatocytes also is important in 
achieving efficient function. Intraportal, intrasplenic, 
and intraperitoneal infusions all have relative 
strengths and shortcomings. For instance, infusion of 
large numbers of hepatocytes into the portal vein can 
induce portal hypertension. 
Hepatocyte transplantation for transfer of genes to 
individuals with genetic diseases has advanced from 
animal experimentation to pilot trials in humans. This 
approach was developed in the hypercholesterolemic 
Watanabe rabbit, which has a genetic defect in the low- 
density lipoprotein (LDL) receptor similar to that of 
humans with familial hyper~holesterolemia.~~ Hepato- 
cytes were obtained from the animals by partial hepatic 
resection, grown in cell culture, and then transfected 
with the normal rabbit LDL receptor gene using a ret- 
rovirus vector. After reinfusion into the portal vein, the 
viability of the hepatocytes was shown functionally by 
decrease in serum cholesterol and histologically by 
identification of transfected hepatocytes expressing 
normal LDL receptor messenger RNA (mRNA). Ap- 
proximately 2% of normal functional hepatocyte mass 
was provided by the transplanted hepatocytes, and 
these cells continued to function for several months. 
These innovative studies have led to pilot trials of au- 
tologous hepatocyte transplantation in humans with 
homologous type I1 hyper~holesterolemia.~~ 
There have been few studies on hepatocyte trans- 
plantation for FHF. Using an animal model of liver 
insufficiency, Demetriou et a1 have evaluated the abil- 
ity of transplanted hepatocytes to provide liver sup- 
Rats underwent 90% hepatectomy, which led to 
death in 24 ? 8 hours after surgery in controls. Animals 
treated with infusions of either allogeneic or syngeneic 
hepatocytes before hepatectomy survived for 28 ? 8 
hours. Infusions of hepatocytes at the time of hepatec- 
tomy also did not prolong survival. One limitation in 
using hepatocyte transplantation for treating FHF is 
the need for a period of 1 to 3 days for cell engraftment 
before function. In addition, the altered milieu of FHF 
may not provide a suitable environment for trans- 
planted hepatocytes: the same toxin that harmed the 
native liver may harm the infused liver cells, and the 
usual hepatic architecture and balance of growth fac- 
tors, cytokines, and nutrients necessary for hepatocyte 
growth and regeneration may be lacking in FHF. Thus, 
hepatocyte transplantation is a promising approach to 
hepatic support in FHF but has yet to be developed 
sufficiently to attempt its use in patients. Because of 
limitations in the numbers of hepatocytes that can be 
transplanted successfully, this technique may be more 
applicable to other situations, such as correction of in- 
herited metabolic defects. 
PROSTAGLANDIN THERAPY FOR FHJ? 
Specific therapies for FHF are not currently avail- 
able. Antiviral therapies have shown little evidence of 
benefit.56-58 On the other hand, therapies directed at 
limiting cell damage, providing cytoprotection, and 
stimulating regeneration might have a role in manage- 
ment of FHF. Among cytoprotective agents, the prosta- 
glandins have been most actively investigated. 
Dr Gary A. Levy (Director, Division of Gastroenterol- 
ogy, Department of Medicine, Toronto General Hospi- 
tal, Toronto, Ontario, Canada) provided an overview 
on prostaglandins and their potential role as therapy 
of FHF. The prostaglandins are a group of polyunsatu- 
rated fatty acids with major, diverse metabolic actions 
on cells.59 Prostaglandins are made in all cells, the liver 
being particularly rich in the prostaglandin E (PGE) 
series. When administered systemically, PGE has mul- 
tiple effects on smooth muscle tissue, inducing wide- 
spread vasodilation, increased blood flow, hypotension, 
increased cardiac output, bronchodilation, intestinal 
hypermotility, and uterine contractions. Exogenously 
administered prostaglandins can protect the liver 
against several forms of cell injury, including hypoxic, 
drug-induced, viral, and immune injury.60,61 The avail- 
ability of PGEl and PGE, for human use has provided 
an impetus to evaluate these agents in several liver 
diseases, including FHF. 
Sinclair et a162 from Toronto, Canada, evaluated 
PGEl in 17 patients with FHF in an open label-pilot 
study. PGE, was administered by continuous intrave- 
nous infusion at a rate of up to 0.6 pg/kg/hr for as 
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long as 28 days. Infusions of PGE, were generally well 
tolerated. Several patients had prompt improvements 
in aminotransferases. Most impressively, 12 patients 
survived without transplantation, a rate (70%) far in 
excess of that in most series on FHF. Unfortunately, a 
subsequent uncontrolled study of FHF from France63 
failed to confirm the benefit of prostaglandin therapy. 
Based on their initial beneficial results, Levy et a164 
began a prospective, randomized, double-blind con- 
trolled study of PGEl therapy in cases of viral- and 
drug-induced FHF. Forty-one patients with FHF were 
admitted to  this trial; 20 received PGE1, and 21 re- 
ceived placebo by continuous intravenous infusions for 
up to  7 days. Overall survival was similar with both 
treatments: 40% of PGEl and 38% of placebo recipients 
survived. Analysis of subgroups suggested that there 
might be some benefit of PGEl therapy in patients with 
drug-induced FHF and viral hepatitis early in its 
course. However, diarrhea, fever, and mild hypotension 
occurred in patients receiving PGEl therapy. In view 
of these findings, routine use of prostaglandins for FHF 
outside of controlled trials must be discouraged. 
EXTRACORPOREAL LIVER SUPPORT 
Dr Byers Shaw (Chairman, Liver Transplantation 
Program, University of Nebraska, Medical School, 
Omaha, NE) summarized recent experience using an 
extracorporeal liver (ECL) support system in the man- 
agement of FHF. In this technique, the patient's circu- 
lation is connected to  a liver outside of the body. The 
organ used for cross circulation may be human or from 
another species. The procedure was introduced by Otto 
in the late 1950s and then used sporadically. During 
the 1970s, 40 patients with more than 90 episodes of 
FHF were treated; 3 donors were human, 67 were pri- 
mates, 23 were pigs, and 2 were calves; acute survival 
was 35%.65 
The University of Nebraska has recently applied this 
technique using unwanted human donor livers in three 
patients with FHF.65 The patients were a 16-year-old 
and a 38-year-old with FHF of unknown cause and a 
6-year-old with Stevens Johnson syndrome. The first 
patient underwent ECL support for 3 days with rapid 
improvements in serum bilirubin and ammonia levels 
and decreases in ICP. The second patient underwent 
treatment for 24 hours using a liver with marked fatty 
infiltration; there was minimal improvement in biliru- 
bin and ammonia levels. The first two patients subse- 
quently underwent transplantation successfully. The 
third patient underwent perfusion for 3; days with de- 
crease in bilirubin and ammonia but progressive fail- 
ure of other organ systems and death. 
Five cases of ECL support using livers of other spe- 
cies have been reported recently from other institu- 
tions. At Johns Hopkins University Medical Center, a 
porcine liver was used for 4 hours in a 20-year-old pa- 
tient with FHF caused by hepatitis B: consciousness 
improved, and the patient underwent successful OLTx 
8 hours later.66 Four patients were treated with ECL 
support using porcine liver at  Duke University Medical 
TABLE 7. Median Survival Time After Hamster-to-Rat 
Xenotransplantation 
Immunosuppressive Heart Survival Liver Survival 
Regimen (d) (d) 
None 3 7 
FK506 alone 4 35 
FK506 + cyclophosphamide >90 > 90 
FK506 + brequinar >90 > 90 
Center; transient improvements in neurological status, 
ICP, and hepatic function occurred in all four patients. 
One patient received an OLTx after four perfusions and 
is well; the other three died of sepsis, cerebral edema, 
and multisystem failure, re~pec t ive ly .~~ 
Thus, the conditions of four of eight patients in the 
modern era have been managed successfully with ECL 
support, bridging the period of FHF until OLTx could 
be performed. Deaths that occurred in three patients 
were unrelated to the ECL technique. Thus, ECL sup- 
port offers an attractive means of temporary support 
for patients with severe FHF. Improvements in han- 
dling ECL, monitoring its efficacy, and handling prob- 
lems of species incompatibility are needed before this 
technique can be more broadly applied. 
XENOTRANSPLANTATION 
Dr John Fung (Chief, Division of Transplantation 
Surgery, University of Pittsburgh, Pittsburgh, PA) pro- 
vided an update and overview on xenotransplantation 
and its potential role in management of FHF. The con- 
cept of using a xenograft for transplantation is not new. 
Before 1992, 33 human xenotransplantations were re- 
ported, most before the availability of cyclosporin A and 
FK506. The longest survival was 9 months, reported 
in a patient given a chimpanzee kidney.68 The most 
successful previous experience with baboon xenotrans- 
plantation was in a neonate with hypoplastic left-heart 
syndrome who received a baboon heart and survived 
20 days, dying eventually of humoral-mediated rejec- 
t i ~ n . ~ '  Thus, xenotransplantation was unsuccessful 
largely because of problems with humoral and cell-me- 
diated rejection. 
The development of FK506 has allowed for a reas- 
sessment of xenotransplantation. In animal studies, 
FK506 by itself does not prolong survival of hamster 
heart xenografts in rats; however, the combination of 
FK506 with antiproliferative drugs, such as with 
RS61443, brequinar, or cyclophosphamide, does.7" In 
liver xenografts, combinations of FK506 with antipro- 
liferative agents led to indefinite survival of grafts (Ta- 
ble 7). The antiproliferative agents seem to act by 
blocking formation of cytotoxic antibodies and eventu- 
ally can be discontinued, whereas FK506 blocks devel- 
opment of cellular rejection, and continuous therapy is 
needed. 
These experiments prepared the way for attempts at  
xenotransplantation in humans. The general protocol 
of therapy used depletion of any natural antibody 
250 HOOFNAGLE ET AL. HEPATOLOGY January 1995 
using plasmapheresis and affinity absorption, disrup- 
tion of the inflammatory cascade with corticosteroids, 
blockage of antibody production by cyclophosphamide 
and/or breauinar, and inhibition of cellular rejection 
mission of infections remain as very significant is- 
s u e ~ . ~ ~  
SUMlvLARY AND RECOMMENDATIONS 
with FK506 and corticosteroids. 
Recently two types of xenograft donors have been 
evaluated: pigs and baboons. Porcine xenotransplanta- 
OLTx should be considered standard management 
for Patients with FHF who are in stage 111 to IVhepatic 
that survival with medical therapy alone is unlikel~ 
tion was used by investigators from Cedars sinai H~~. 
ill patient with FHF until an appropriate human donor 
liver was available.7i After plasmapheresis against a 
porcine kidney to reduce antiporcine antibodies, the 
patient underwent xenotransplantation under therapy 
with cyclosporin A, azathioprine, cyclophosphamide, 
and corticosteroids. Initial hepatic xenograft function 
was good, but after 25 hours the graft began to fail, ICP 
rose, and she died a few hours later. Autopsy showed 
widespread hepatic necrosis with plugging and throm- 
bosis of arterioles and presence of immunoglobulin G 
(IgG) on endothelial cells throughout the liver. Similar 
pathology was noted in porcine livers used in cross- 
circulation studies in patients with FHF.72 Thus, prob- 
lems of immediate rejection and incompatibility limit 
the usefulness of porcine livers in xenotransplantation 
as well as extracorporeal liver support for FHF. 
tis B received orthotopic baboon liver xenografts at the 
University of Pittsburgh Medical Center.73 The ratio- 
nale for xenotransplantation in these patients was that 
the baboon is not susceptible to  hepatitis B and there- 
fore reinfection could be avoided.74 The patients and 
baboons were carefully matched for blood type and ab- 
sence of pre-existing IgG xenoantibodies. Immunosup- 
pressive therapy included FK506, cycbhosPhamide7 
and corticosteroids. Initial graft function was good. The 
baboon livers were small in comparison with those of 
humans (450 to 550 g Vs- 1,200 to 1,500 g) but grew 
rapidly to a size appropriate to  the recipient. In both 
cases, baboon Proteins (albumin, transferrin, c3) were 
detected in serum, but functions seemed normal (coag- 
ulation and complement cascade). Unfortunately, both 
Patients developed Persistent, Poorly explained jaun- 
dice, multiple infections, and multisystem failure. Pa- 
tient no. 1 died after 74 days with invasive aspergillo- 
sis; patient no. 2 died after 26 days with septicemia. 
Thus, the results of xenotransplantation to date are 
promising but far from satisfactory. Baboon liver xeno- 
transplantation for FHF has not been reported but may 
also be appropriate in view of the increasing problem 
of human donor liver availability and the possibility of 
using the baboon liver to  sustain the critically ill pa- 
tient with FHF until an appropriate human liver is 
available. The problems that blocked success in the 
past, immediate vascular rejection and severe cellular 
rejection, seem to be manageable with appropriate im- 
munosuppression, at least with baboon livers. What 
remains are problems of a technical and metabolic na- 
ture. Furthermore, the shortage of baboons, ethical 
considerations in using primates, and issues of trans- 
encephalopathy and who fulfill criteria that indicate 
and that irreversible neurological damage has not OC- 
curred. Long-term survival in such patients with FHF 
is similar to  that of patients with chronic end-stage 
liver disease, if adverse donor (ABO incompatibility) 
and recipient factors (need for ventilatory support) are 
controlled for in the analysis. Strict criteria for patient 
selection and timing of OLTx are of great importance in 
the outcome of transplantation: the decision to perform 
OLTx in FHF should be based on careful assessment 
of both static and dynamic factors. Static factors of 
importance are of FHF and patient age. Dynamic 
factors of importance are stage of encephalopathy, pro- 
thrombin time (or factor V levels), serum bilirubin, cre- 
atinine, arterial pH, and alpha-fetoprotein levels. Med- 
ical models for predicting survival are of great help in 
reaching a decision for OLTx. Exclusion criteria are 
also important: overwhelming infections and sustained 
for OLT, which makes careful for infections 
and intracerebral pressure essential. At the present 
time, use of innovative approaches to managing FHF, 
such as auxiliary transplants, living related donors, 
xenografts, extracorporeal human liver, and artificial 
hepatic support devices, are extremely promising but 
must be considered experimental. 
Several recommendations can be made to improve 
the general management ofpatients with FHF. In med- 
ical practice, important goals are (1) encouragement of 
early referral of patients with FHF to transplantation 
centers, and (2) increased use of HAV and HBV vaccine. 
In public policy, important steps are (1) creation of a 
new UNOS category for patients with acute FHF, (2) 
increased public programs to promote awareness about 
organ donation, (3) change in reimbursement practices 
for OLTx for patients with FHF by Medicare and Med- 
icaid, and (4) more aggressive labeling guidelines for 
hepatotoxic drugs. In clinical research, important areas 
are (1) prospective studies on the epidemiology of FHF, 
(2) development of clear diagnostic criteria and better 
coding systems for this diagnosis, and (3) careful design 
and performance of clinical trials of new and innovative 
approaches to  management and treatment of FHF. In 
basic research, important studies are (1) in u&-o and 
in uiuo analyses of the causes of brain edema in FHF, 
(2) analyses of the role of cytokines and hepatotrophic 
growth factors in liver cell injury and FHF, (3) basic 
virological and cell biological investigations into the 
etiology of cryptogenic FHF (non-A, non-B, and non-C 
hepatitis), and (4) development of animal models of 
severe hepatic injury to  aid in the study of pathogenesis 
as well as therapy and management of FHF. 
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